Genelux (GNLX) Net Cash Flow (2022 - 2026)
Genelux (GNLX) posted quarterly Net Cash Flow of $3.9 million for Q1 2026, down 48.44% year-over-year from $7.6 million in Q1 2025, and up 514.66% quarter-over-quarter from $641000.0 in Q4 2025.
Genelux (GNLX) Net Cash Flow (2022 - 2026) Analysis & Trends
Genelux's Net Cash Flow history runs 5 years deep, the most recent figure standing at $3.9 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 48.44% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at -$6.9 million (down 157.09% YoY), while the FY2025 annual figure was -$3.2 million, down 278.9% from the prior year.
- Net Cash Flow for Q1 2026 stood at $3.9 million, up from $641000.0 in the prior quarter.
- The five-year high for Net Cash Flow was $16.8 million in Q2 2023, with the low at -$20.5 million in Q4 2023.
- The 5-year median for Net Cash Flow is $2.5 million (2024), against an average of $705533.3.
- Peak annual rise in Net Cash Flow reached 270.93% in 2023, while the deepest fall reached 2001.85% in 2023.
- Genelux's Net Cash Flow stood at -$973000.0 in 2022, then tumbled by 2001.85% to -$20.5 million in 2023, then jumped by 112.04% to $2.5 million in 2024, then plunged by 73.97% to $641000.0 in 2025, then soared by 514.66% to $3.9 million in 2026.
- Business Quant data shows GNLX's Net Cash Flow at $3.9 million in Q1 2026, $641000.0 in Q4 2025, and -$1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Genelux | 119.87 Mn | 119.87 Mn | - | 3.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.94 Mn |
| Mar 31, 2026 | 3.94 Mn |
| Dec 31, 2025 | 641,000.00 |
| Dec 31, 2025 | 641,000.00 |
| Sep 30, 2025 | -1.85 Mn |
| Sep 30, 2025 | -1.85 Mn |
| Jun 30, 2025 | -9.67 Mn |
| Jun 30, 2025 | -9.67 Mn |
| Mar 31, 2025 | 7.64 Mn |
| Mar 31, 2025 | 7.64 Mn |
| Dec 31, 2024 | 2.46 Mn |
| Dec 31, 2024 | 2.46 Mn |
| Sep 30, 2024 | -1.76 Mn |
| Sep 30, 2024 | -1.76 Mn |
| Jun 30, 2024 | 3.80 Mn |
| Jun 30, 2024 | 3.80 Mn |
| Mar 31, 2024 | -5.36 Mn |
| Mar 31, 2024 | -5.36 Mn |
| Dec 31, 2023 | -20.45 Mn |
| Dec 31, 2023 | -20.45 Mn |